How Post-Approval GMP Challenges Cooled Novo Nordisk’s Blazing Wegovy Launch
Executive Summary
Unrelated US FDA inspection led contract manufacturer to stop filling Wegovy syringes before alternate manufacturing facilities became available.
You may also be interested in...
Novo Nordisk Has A Plan To Get Wegovy Launch Back On The Rails
The company is targeting revenues of DKK25bn ($3.66bn) from Wegovy for obesity in 2025, with plans to amp up the US launch this year following an initial supply disruption.
Wegovy Manufacturing Delays Highlight Challenges Of Managing Aging Facility Risks
While pharmaceutical manufacturing facilities can age well, the care and attention aging facilities require can arise at inopportune moments, as was the case for Novo’s Wegovy launch. Even so, Catalent aims to make quick work of air handler replacement to get the new weight-loss drug back into production, despite typically long lead times, consultant says.
Novo Nordisk’s Diabetes Franchise Bears The Weight Of Disappointing Obesity Sales
The Danish firm’s GLP-1 drugs are behind much of its 2021 sales success as ongoing problems with the manufacturing of in-demand obesity product Wegovy dampen growth.